Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
about
Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2SYK is a critical regulator of FLT3 in acute myeloid leukemiaA decade of exploring the cancer epigenome - biological and translational implicationsEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesTargeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesTargeting histone methyltransferases and demethylases in clinical trials for cancer therapyDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsEpigenetic regulators and their impact on therapy in acute myeloid leukemiaDysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapyMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceOpen access chemical probes for epigenetic targetsMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementSynthesis of lysine methyltransferase inhibitorsStructural and functional coordination of DNA and histone methylationChemical probes of histone lysine methyltransferasesDesign of small molecule epigenetic modulatorsTargets, models and challenges in osteoarthritis researchEpigenetics: the fine-tuner in inflammatory bowel disease?Mechanisms of epigenetic regulation of leukemia onset and progressionRecent progress toward epigenetic therapies: the example of mixed lineage leukemiaEpigenetic regulators as promising therapeutic targets in acute myeloid leukemiaHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionConcise review: Leukemia stem cells in personalized medicineCurrent chemical biology approaches to interrogate protein methyltransferasesThe next steps in next-gen sequencing of cancer genomesCancer epigenetics drug discovery and development: the challenge of hitting the markHijacked in cancer: the KMT2 (MLL) family of methyltransferasesEpigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancerSelective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic StudiesPotent inhibition of DOT1L as treatment of MLL-fusion leukemiaConformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1LA selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsStructures of NS5 Methyltransferase from Zika VirusCell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activityEpigenetic Therapeutics: A New Weapon in the War Against CancerEmerging concepts of epigenetic dysregulation in hematological malignanciesHistone lysine methyltransferases as anti-cancer targets for drug discoveryEpigenetics in Cancer: A Hematological PerspectiveEpigenome-based personalized medicine in human cancerThe PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
P2860
Q24300459-9EF87EF0-69BE-4C59-BDC8-5942E97C7849Q24337247-0CC2E6A9-4FE4-4285-B3A9-39196E4D5708Q24614467-0574DC48-AE04-4C16-B046-0AE8A8FE4B74Q26744080-FDA3B2B5-3531-406B-8433-338A6420737FQ26744441-0876CC87-3B99-46FA-84C2-DBD905411EEAQ26746038-06616DA2-0F32-4473-BF57-A5D53418BCDEQ26749421-870C70EE-4B54-46BB-AD65-4341CBB20C8DQ26765402-79A6B3FD-DDE3-4434-AAFC-BDF7DDC12625Q26769943-34B179E7-BA50-4287-B45C-F422979B73DAQ26776393-14005CAE-70B9-48CC-BDBD-57469B42B5A1Q26781872-E2922E45-1D86-4FB9-97B3-348210B61101Q26785379-8CB48110-E718-441D-8DB8-EE3579A37BA3Q26799953-71DEE407-B6A7-44A6-89E3-888247CD458CQ26825534-5FE7C6A6-D8AB-42AD-B458-BFA96B408ACDQ26829218-1877CE7A-5E79-4822-92B4-4C1A736D6E5BQ26850027-10E701CC-1522-4B08-AD3D-472F81D8B9C1Q26850147-DFC1FBA8-D924-4548-9008-C882566585F8Q26853555-0C8D4135-3A04-4357-8730-6EFF56169EB0Q26861785-EA655D23-C56F-489C-9A44-9A37E1695071Q26863577-15E3582E-04A7-4277-BA93-C675F5E98530Q26865149-05DE44C9-BAF1-46E5-AD5A-130E79CF3D77Q26994739-07E8DE21-9BAF-4367-940B-4A357674F66BQ26995268-6037E617-C25D-4833-95D0-00125160E3C5Q26995430-FBA30C99-3D18-4F9C-BFAC-D7543D284360Q26998894-9595C802-B335-44FB-AD76-81E67D90A7AFQ27002333-C435F4D4-FFA2-434D-ABE4-3700D7CB3AD0Q27006839-805F13DE-A4AB-480A-AEF7-A9CB8D708E0DQ27022720-ADC24749-058C-4F9F-895D-67073F394DE9Q27674356-8AE4EBD6-76A2-43EB-B7BF-675C686A7A69Q27678800-8569B661-5F16-4396-A5AA-1ED78FE9000FQ27682251-F4719E43-74EB-4A3E-A89D-5F221132F0E0Q27700259-794A20C5-5E90-4D50-A75C-3172E0BC6A99Q27928070-0A8E407B-3AF0-47CE-A46A-A85D62AE0EB3Q28070111-F016CEB5-9E02-41CD-9ACF-CB0D393E739DQ28072370-FE70A939-8854-4DEE-8C9F-BBCD30D6B574Q28074522-5DCB08E4-ED73-44CD-9ADB-106A9386F434Q28076288-102207E7-FB62-4DA1-BB5C-E716DBAF5962Q28077082-FF22F984-B015-43CC-A1A8-C42756AC44E9Q28083951-D16C395A-EFAC-4A3C-9E02-EFA0716989C5Q28085672-A61F4EAE-CC9E-41F4-A350-9F6D0B8BF3EC
P2860
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.
@ast
Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.
@en
type
label
Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.
@ast
Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.
@en
prefLabel
Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.
@ast
Selective killing of mixed lin ...... mall-molecule DOT1L inhibitor.
@en
P2093
P2860
P50
P1433
P1476
Selective killing of mixed lin ...... small-molecule DOT1L inhibitor
@en
P2093
Carly A Therkelsen
Christina R Majer
Christopher J Sneeringer
Edward J Olhava
Jeffrey Song
Jen-Chieh Tseng
Jesse J Smith
Kevin W Kuntz
L Danielle Johnston
P2860
P356
10.1016/J.CCR.2011.06.009
P577
2011-07-01T00:00:00Z